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A B S T R A C T
Background: Type 2 diabetes mellitus (DM) and HIV increase the risk of tuberculosis (TB). The frequency
of DM among patients with TB with and without HIV is poorly documented in many low- and middle-
income countries.
Methods: This was a cross-sectional hospital-based study performed in Abuja, Nigeria. Adults with
presumptive TB were screened consecutively. Sputum culture was used for TB screening and blood was
used for HIV screening, as well as fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c)
assessment for the diagnosis of DM. HbA1c was measured using the D-10 Haemoglobin Testing System
and a point-of-care test (A1C Now+ system) for comparison. Patients were classiﬁed as having DM or pre-
diabetes using the D-10 reference test.
Results: Four hundred and ten individuals had TB culture, FPG, and HbA1c results. Participants had a mean
( standard deviation) age of 37.8  12.6 years and 217 (54.8%) were male. One hundred and thirteen
(27.6%) patients were culture-positive, 62 (15.1%) had DM, and 46 (11.2%) had pre-diabetes. One hundred
and eighty-four (53.3%) participants were HIV-positive and 95 (51.6%) were on antiretroviral therapy
(ART). Patients with pre-diabetes and DM were more likely to have TB (odds ratio (OR) 1.94, 95%
conﬁdence interval (CI) 0.01–3.74, and OR 2.39, 95% CI 1.35–4.24, respectively). After adjustment for HIV,
age, and sex, only DM was statistically associated with TB (adjusted OR (AOR) 3.10, 95% CI 1.62–5.94). HIV-
negative patients with DM had a higher risk of TB (AOR 4.32, 95% CI 1.57–11.92) than HIV-positive
patients with DM (AOR 3.31, 95% CI 1.29–8.54), but the difference was not statistically signiﬁcant. A1C
Now+ HbA1c measurements correlated poorly with the D-10 HbA1c reference test.
Conclusion: A high proportion of patients in Abuja have markers of DM and pre-diabetes at the time of TB
diagnosis.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) remains an enormous burden and a challenge
to public health in low- and middle-income countries (LMIC)
(Uplekar et al., 2015). Nigeria, the most populous country in Africa,
has one of the highest burdens of TB in the world, with a prevalence* Corresponding author at: Liverpool School of Tropical Medicine, Pembroke
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).of 524 TB cases per 100 000 population (Anon., 2012). TB as a
public health problem resurfaced with the emergence of HIV in the
1980s (Ronacher et al., 2015), currently affecting 3.34% of Nigerian
adults. Nigeria has the second largest burden of HIV worldwide
(Bashorun et al., 2014), and an estimated 27% of TB cases are co-
infected with HIV, although this proportion is not evenly spread
across the country (Umeh et al., 2007; Lawson et al., 2009; Iliyasu
and Babashani, 2009).
Lifestyle changes have also led to an emerging epidemic of type
2 diabetes mellitus (DM), affecting an estimated 366 million
people worldwide, with 80% living in LMIC (Aguiree et al., 2013).
The intensive urbanization of Nigeria over recent decades has
witnessed a large increase in DM from <1% of adults in the 1970s to
5% in 2013 (Aguiree et al., 2013).iety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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detrimental effects on health. DM is present in an estimated 15% of
TB cases (Stevenson et al., 2007a), and TB rates are higher among
those with the more severe DM phenotypes (Swai et al., 1990).
Diabetic patients with TB have a higher mycobacterial burden than
non-diabetics (Dave et al., 2013), require a longer time to culture
conversion (Dooley et al., 2009), have a four times higher risk of
treatment failure (Morsy et al., 2003), and have an over six times
higher risk of death (Dooley et al., 2009).
HIV and DM increase the risk of TB, although the frequency of
DM among patients with TB with and without HIV in LMIC is poorly
documented and often counterintuitive. For example, Tanzanian
patients with DM were found to have increased odds of TB among
HIV-negative but not among HIV-positive patients (Faurholt-
Jepsen et al., 2011), and DM was found to increase the risk of death
among HIV-negative but not among HIV-positive patients with TB
(Faurholt-Jepsen et al., 2013). Further studies are needed to
examine these associations.
The diagnosis of DM in LMIC is often limited by the difﬁculty in
measuring fasting plasma glucose (FPG), and the World Health
Organization (WHO) recommends the use of glycated haemo-
globin (HbA1c) as a more practical and reliable indicator of DM.
HbA1c measures the percentage of glucose attached to haemo-
globin (or glycosylated) and reﬂects the average blood sugar
levels for the preceding 8–12 weeks. Measurements of HbA1c can
be performed at any time of the day, and easy-to-use, portable
kits have become available (Jiang et al., 2014). One of these, the
A1C Now+ system provides a fast and easy method of obtaining
HbA1c, providing immediate results for patient management.
However, there have been very few ﬁeld evaluations to assess
whether its performance is similar to HbA1c measurements
conducted using validated platforms at reference laboratories in
LMIC.Figure 1. Study ﬂow chart showing thThe association between TB and DM and the relevance of HIV
among patients attending district hospitals in Abuja, Nigeria is
described here. As a sub-study, the agreement of a point-of-care
test (A1C Now+) with the HbA1c reference test (D-10 Haemoglobin
Testing System; Bio-Rad 2020) was also assessed.
Methods
This was a cross-sectional hospital-based study performed in
Wuse and Nyanya district hospitals in Abuja Federal Capital
Territory, Nigeria. Consecutive adults >18 years old with a cough of
2 weeks duration (presumptive TB), presenting spontaneously to
the TB diagnostic and treatment clinics of the hospitals or referred
from the general outpatient and HIV clinics for TB screening, were
invited to participate. After obtaining written informed consent,
patients were interviewed using a structured questionnaire to
obtain demographic data and medical history. Individuals were
invited to participate if they were adults and were not receiving
anti-TB treatment, or had not received treatment in the preceding
2 months. Three sputum specimens were collected using routine
procedures over a 2-day period. Venous blood samples were
collected for diabetes testing at the study clinics the morning of the
second day, after overnight fasting. Blood samples were distributed
into bottles containing ﬂuoride oxalate and ethylenediaminetetra-
acetic acid (EDTA), and transported in a cold chain to Zankli
Tuberculosis Research Laboratory for testing within a maximum of
5–6 h of collection.
Sputum specimens were tested using light emission diode
ﬂuorescence microscopes (LED-FM), Gene Xpert, and culture on
BACTEC MGIT 960. Patients were classiﬁed as having TB if the
culture was positive. HIV counselling and testing were offered to all
patients in the context of routine services and national guidelines.
Patients were tested while in the clinic using two HIV rapide inclusion and exclusion criteria.
Table 1
Characteristics of the study participants.
Participants (N = 410)
Age, years, mean  SD 37.8  12.6
Male to female ratio (% male) 227:183 (55.4)
TB culture Positive 113 (27.6)
Negative 297 (72.4)
TB treatmenta None 352 (87.3)
Previously treated 51 (12.7)
TB symptoms Weight loss 281 (69.2)
Weakness 268 (66.0)
Fever 259 (63.8)
Chest pain 242 (59.6)
Night sweats 201 (49.5)
Loss of appetite 200 (49.3)
HIV Positive 184 (45.9)
Negative 161 (40.1)
Unknown 65 (15.9)
ART On ART 95 (27.5)
No ART 63 (18.3)
Unknown 26 (7.5)
No HIV 161 (46.7)
HbA1c (%) >6.4 51 (12.6)
6.0–6.4 48 (11.8)
<6.0 307 (75.6)
Known diabetesb 17 (4.2)
HbA1c >6.4 or known diabetesb 62 (15.1)
FPG mg/dl 126 23 (5.6)
100–125 32 (7.8)
99 344 (83.9)
Unknown 11 (2.7)
LDL mg/dl 100 119 (29.0)
<100 263 (64.1)
Unknown 28 (6.8)
HDL mg/dlc Low 207 (50.5)
Normal 175 (42.7)
28 (6.8)
Total cholesterol mg/dl 200 48 (11.7)
<200 334 (81.5.4)
Unknown 28 (6.8)
Triglycerides mg/dl 200 27 (6.6)
150–199 35 (8.5)
<150 319 (77.8)
ART, antiretroviral therapy; FPG, fasting plasma glucose; HbA1c, glycated
haemoglobin; HDL, high density lipoprotein; HIV, human immunodeﬁciency virus;
LDL, low density lipoprotein; SD, standard deviation; TB, tuberculosis.
a Information missing for seven patients.
b Diabetes: HbA1c >6.4 or self-reported diabetes. Pre-diabetes: HbA1c 6.0–6.4.
c HDL: high is 40 mg/dl for men and 50 mg/dl for women; normal is <40 mg/dl
for men and <50 mg/dl for women.
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receiving antiretroviral therapy (ART). ART was offered to HIV
patients following the national guidelines.
FPG was measured using a Hemolyzer and HbA1c was analysed
using the D-10 Haemoglobin Testing System (Bio-Rad 2020) at the
routine laboratory of Zankli Medical Centre; FPG tests were run in
parallel with standard quality controls with every batch of the
reagent kit. The A1C Now+ system was also used while patients
were still in the clinic to assess the correlation of results with those
of the D-10 Haemoglobin Testing System. The D-10 system
measurements of HbA1c were considered the reference standard
for the comparison of tests and was used to indicate the presence
of DM in the risk factor analyses. Pre-diabetes was deﬁned as
HbA1c between 6.0% and 6.4% and DM as HbA1c >6.4% or self-
reported DM at the time of the interview.
Statistical analyses were performed using IBM SPSS Statistics
version 22.0 (IBM Corp., Armonk, NY, USA). The associations of TB
with HIV and DM were investigated using univariate and
multivariate logistic regression analysis. A multivariate model
was adjusted for all the variables signiﬁcantly associated with TB in
the univariate tests. The analyses of the association of TB and DM/
pre-diabetes were repeated separately according to HIV status and
adjusted. p-Values of <0.05 were considered statistically signiﬁ-
cant. The agreement of the Bio-Rad 2020 and the point-of-care test
A1C Now+ system was assessed using the Spearman correlation
test for continuous values of HbA1c and kappa statistics for
categorical data.
Ethical approval was obtained from the Federal Capital Territory
Research Ethics Committee. All participants were asked to provide
written informed consent to participate.
Results
A total of 663 individuals were invited to participate. Of these,
479 had valid TB culture results and 410 had valid information to
ascertain DM status (406 had HbA1c measurements and four had a
known DM diagnosis) and were selected for analysis (Figure 1). The
mean ( standard deviation) age of the participants was
37.8  12.6 years and 227 (55.4%) were male.
One hundred and thirteen (27.6%) patients were culture-
positive for TB and 297 (72.4%) were culture-negative. Sixty-two
(15.1%) had DM, 46 (11.2%) had pre-diabetes, and 302 (73.7%) were
euglycaemic. Six (9.7%) of the DM patients were aware and 52
(90.3%) were unaware of their DM (information was missing for
four). Among the 410 participants, HIV status was known in 345
(84.1%) and unknown in 65 (15.9%) participants. The latter
included patients who did not want to provide information from
previous tests and those who refused testing.
One hundred and eighty-four (53.3%) were HIV-positive and
161 (46.7%) were HIV-negative. Among the HIV-positive patients,
95 (51.6%) were receiving ART at the time of data collection, as
described in Table 1. One hundred and nineteen (29%) participants
had high LDL concentrations (low density lipoprotein), 207 (50.5%)
had low HDL concentrations (high density lipoprotein), and 27
(6.6%) had high triglycerides.
Factors associated with a positive Mycobacterium culture in the
univariate analysis were the presence of pre-diabetes or DM, not
having HIV, being male, and being aged between 18 and 28 years
(Table 2). Patients with and without TB had similar lipid proﬁles,
except for HDL, which was more likely to be low among patients
with TB (67% and 49%, respectively; odds ratio (OR) 2.1, 95%
conﬁdence interval (CI) 1.3–3.4). Patients with pre-diabetes or DM
were more likely to be culture-positive than non-diabetics (OR
1.94, 95% CI 0.01–3.74, and OR 2.39, 95% CI 1.35–4.24, respectively).
HIV-positive patients were less likely to have positive culture than
HIV-negative patients (OR 0.44, 95% CI 0.27–0.70), and receivingART did not affect the likelihood of a positive culture. After
adjustment for HIV status, age, and sex, only the association
between TB and DM remained statistically signiﬁcant (adjusted OR
3.10, 95% CI 1.62–5.94). A higher proportion of HIV-positive
patients than HIV-negative patients had DM (30 (18.6%) vs. 26
(14.1%)) or pre-diabetes (19 (11.8%) vs. 18 (9.8%)), but these
differences were not statistically signiﬁcant (p > 0.05). Similarly,
there was no statistically signiﬁcant association between the use of
ART and DM (p > 0.05).
After adjusting for age and sex, the association between HIV and
DM was not statistically signiﬁcant. Whether HbA1c values
differed between patients with and without conﬁrmed TB and
HIV status was analysed further. Patients with TB had higher
Hb1Ac than patients without TB (5.8% and 5.4%, respectively;
p < 0.001). The difference was similar for patients with and
without HIV co-infection (p = 0.26), as shown in Table 3. The
agreement between the A1C Now+ system and the reference test
showed a moderate correlation (r = 0.34, p < 0.01), with a kappa
value of 12.6%, corresponding to poor agreement. The test had a
sensitivity of 50% (95% CI 25.5–74.5) and speciﬁcity of 74.5% (95% CI
65.2–82.1%) when using a cut-off of 6.5%.
Table 2
Factors associated with tuberculosis on univariate and multivariate analysis.
Conﬁrmed TB, n (%) OR (95% CI) AOR (95% CI)a p-Value
Yes No
Diabetes status Diabetesb 26 (23.0) 36 (12.1) 2.39 (1.35–4.24) 3.10 (1.62–5.94) 0.001
Pre-diabetes 17 (15.0) 29 (9.8) 1.94 (0.01–3.74) 1.81 (0.82–3.97) 0.14
No diabetes 70 (61.9) 232 (78.1) 1 1
HIV Positive 37 (38.5) 147 (59.0) 0.44 (0.27–0.70) 0.55 (0.32–0.95) 0.03
Negative 59 (61.5) 102 (41.0) 1 1
ART On ART 20 (57.1) 75 (61.0) 0.85 (0.40– 1.83) NA
Not on ART 15 (42.9) 48 (39.0) 1
Sex Male 74 (65.5) 153 (51.5) 1.79 (1.14–2.80) 1.80 (1.05–3.10) 0.03
Female 39 (34.5) 144 (48.4) 1 Ref.
Age quartiles 1st 37 (33.9) 57 (19.6) 2.37 (1.28–4.41) 2.68 (1.27–5.63) 0.01
2nd 32 (29.4) 80 (27.6) 1.46 (0.79–2.71) 1.79 (0.86–3.71) 0.12
3rd 17 (15.6) 69 (23.8) 0.90 (0.45–1.82) 1.01 (0.46–2.22) 0.98
4th 23 (21.1) 84 (29.0) 1
AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, conﬁdence interval; NA, Not available; OR, odds ratio; TB, tuberculosis.
a Adjusted for HIV status, age and sex.
b Diabetes: HbA1c >6.4 or self-reported diabetes. Pre-diabetes: HbA1c 6.0–6.4.
Table 3
Median HbA1c concentrations of patients with and without TB by HIV status.
HIV TB Number Mean (SD) HbA1c
Negative Positive 57 6.12 (1.8)
Negative 101 5.53 (1.07)
Positive Positive 37 5.88 (0.85)
Negative 146 5.48 (0.68)
Main effect and interaction (ANOVA) p-Value
HIV 0.26
TB culture result 0.001
HIV  TB culture result 0.47
ANOVA, analysis of variance; HbA1c, glycated haemoglobin; SD, standard deviation;
TB, tuberculosis.
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Patients in Abuja, Nigeria with TB often have markers of DM and
pre-diabetes. Individuals with DM are known to have a higher risk
of developing TB after infection and to experience higher
mycobacterial loads, with those with insulin-dependent DM
having a higher risk than non-insulin-dependent DM patients.
DM also increases the time required for culture conversion, the risk
of treatment failure, and the risk of death (Dooley et al., 2009;
Dooley and Chaisson, 2009). It may thus well be that a signiﬁcant
proportion of patients diagnosed in this study had pre-existing
DM.
On the other hand, it is also well established that infection leads
to inﬂammation, which in turn can lead to hyperglycaemia and
increased HbA1c. Long-term infection with TB is also prone to
cause chronic inﬂammation, and it is possible that a proportion of
the patients had a transient hyperglycaemic state, which is
reversible with treatment (Basoglu et al., 1999). Longitudinal
studies to follow these patients to the end of treatment are thus
needed to ascertain the proportion of patients who continue to
have DM once they have recovered from TB.
The risk of TB in individuals with DM varies geographically. The
highest risk has been reported in Latin America: in Mexico,
patients with DM have a six times higher risk of developing TB than
euglycaemic patients (risk ratio (RR) 6.8) (Ponce-De-Leon et al.,
2004). This is followed by the Paciﬁc Islands (Kiribati, OR 4.7)
(Viney et al., 2015), Asia (OR and RR 2.5–3.5) (Shetty et al., 2006;
Kim et al., 1995; Alisjahbana et al., 2006), and European
populations (UK OR 3.8, Russia OR 2.66) (Jick et al., 2006; Coker
et al., 2006), with the lowest risk reported from North America and
Australia (RR/OR 1.5) (Pablos-Méndez et al., 1997; Perez et al.,
2006; Dyck et al., 2007), although American Hispanics with DMhave a higher risk than white and black American populations
(Pablos-Méndez et al., 1997; Perez et al., 2006). Studies from Africa
are sparse. A study performed in Tanzania and a former Nigerian
study reported that patients with DM had RRs of 2 and 2.2
compared to euglycaemic patients (Faurholt-Jepsen et al., 2011;
Ogbera et al., 2014), while in Guinea-Bissau there was no increased
association (Haraldsdottir et al., 2015).
The risk of TB in DM patients also varies within populations.
Generally, young adult males are reported to have a higher risk
than females and older individuals (Stevenson et al., 2007b;
Nhamoyebonde and Leslie, 2014). In agreement with these reports,
DM patients with TB were more likely to be young and male, and
diabetic men had a higher risk of TB than diabetic women, in the
present study.
Patients with HIV were less likely to have a positive TB culture
than HIV-negative individuals. This is an apparently paradoxical
ﬁnding, as HIV infection is known to dramatically increase the risk
of TB (Pawlowski et al., 2012). Although HIV patients are less likely
to be able to produce inﬁltration and are more likely to have
miliary TB and to have less energy to cough, this ﬁnding is likely
due to the study design. HIV-positive individuals with respiratory
symptoms are more likely to be referred early for TB screening and
this early and repeated screening would likely identify more
patients with TB. As these patients would have received treatment,
they would have been excluded from this study, resulting in a
cohort effect and selection bias, as the patients enrolled would be
less likely to have TB than patients without HIV attending the
clinics for the ﬁrst time. Although, patients with HIV who initiate
ART have been shown to have a higher risk of developing DM (Isa
et al., 2016), the lack of association of DM and TB with HIV may only
become evident after a longer exposure to ART, and longer studies
are needed.
The point-of-care A1c test had poor agreement with the
reference test and its unreliability prevented its further use in the
clinic. Patients with a timely diagnosis of DM could beneﬁt from a
more holistic approach to the treatment of their multiple
conditions. However, tests with poor performance would misclas-
sify patients and further evaluations are needed to identify tests
with adequate performance. The measurement of HbA1c in HIV
also needs further validation, as patients with untreated HIV have
chronic inﬂammation and ART containing protease inhibitors,
nucleoside reverse transcriptase inhibitors, and non-nucleoside
reverse transcriptase inhibitors can cause reversible hyperglycae-
mia. Furthermore, some HbA1c methods are unreliable in the
presence of haemoglobinopathies.
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their HIV status, almost 90% of diabetics were unaware of their
hyperglycaemic status and were not receiving DM medications.
This has signiﬁcance for the patients, as good glycaemic control is
likely to result in a better response to TB treatment. Furthermore,
from a public health perspective, this highlights the need to test for
the glycaemic status in all cases of TB.
DM is a signiﬁcant and increasing risk for TB in LMIC, which
could increase the complexity of patient clinical management and
worsen the treatment outcome. Nigerian TB and general services
need to be aware of the need to screen for DM for its early
identiﬁcation and management.
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